Ultragenyx Pharmaceutical Inc.
Key Metrics
- Previous Close
- $16.70
- 52-Week Range
- $12.73 – $39.89
- Market Cap
- $1.81B
- P/E (TTM)
- —
- EPS (TTM)
- -5.17
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -22.98%
- Gross Margin
- -10.69%
- Operating Margin
- -59.86%
- Profit Margin
- -71.78%
- Current Ratio
- 1.40
- Debt/Equity
- —
- Total Debt
- $1.19B
- Free Cash Flow
- $-179.38M
- Revenue Growth
- 8.10%
- Earnings Growth
- —
- Enterprise Value
- $2.73B
Market Snapshot
About
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases, with approved treatments for metabolic and bone disorders.